Offer Products
Face Care
Hair Care
stationery & office
Tea & Coffee
Baby Wipes
Cream
Baby Essentials
Fragrances
Lip Care
Body Care
Air Freshener
General Actions (Not specific medical benefits for the user)
| Core Action | Mechanism |
| Dual Blood Sugar Lowering | Empagliflozin increases glucose excretion via the urine, while Metformin decreases hepatic glucose production and improves insulin sensitivity, providing two complementary pathways to lower blood sugar. |
| Cardiovascular Protection | The Empagliflozin component is proven to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with Type 2 Diabetes and established heart disease. |
| Weight and Blood Pressure Benefit | Empagliflozin's mechanism of glucose excretion often leads to modest, beneficial reductions in body weight and blood pressure. |
| Improved Compliance | The Extended-Release (XR) formulation of Metformin allows for once-daily dosing, simplifying the treatment regimen and potentially improving adherence. |
⚠️ Important Safety Note: Prescription Medication for Diabetes
Empaglif-M is a serious medication for a chronic condition.
Lactic Acidosis Risk: The Metformin component carries a black box warning for the rare but serious risk of lactic acidosis.
8 Diabetic Ketoacidosis (DKA) Risk: The Empagliflozin component can increase the risk of DKA, even when blood sugar levels are only moderately elevated.
9 Genital Infections: Empagliflozin can increase the risk of genital yeast infections and urinary tract infections.
10
This medication must be taken strictly as prescribed by your endocrinologist or physician, and regular laboratory monitoring is mandatory
Warning! You must be logged in to submit a review.
Login
Customer questions & answers
Customer reviews
0 out of 5